Early Intervention With Biologics for Asthma Remission: Promising or Premature? Authors: Santi Nolasco, Jaime Bernaola, Parameswaran Nair Published: 2026 Biologics targeting key cytokines and receptors of the type 2 (T2) inflammatory pathway have pushed the limits of what is achievable in treatment outcomes. As such, severe asthma ‘remission’ has become an outcome discussed in expert consensus documents [1] and included in observational studies and post hoc analyses [2]. Across definitions of clinical remission—combining symptom control, normalization/stabilization of spirometry and absence of exacerbations or maintenance oral corticosteroids (OCS)—the proportion of patients achieving remission plateaus at 20%–40%, with no substantial differences between biologics [2]. Given asthma's complex immunobiology, it is unsurprising that targeting single cytokine pathways, often guided solely by blood eosinophils, yields remission in no more than 40% of patients. Indeed, when treatments are selected using comprehensive measurements ~60% of patients may achieve clinical remission [3]. Notwithstanding these findings, several studies suggest that longer disease duration reduces the odds of achieving clinical remission [2], as patients with long‐standing, persistently active disease may accumulate greater lung function impairment and comorbidity burden, making clinical remission less likely even when biologic therapy improves exacerbations, corticosteroid use, and symptoms [4]. This prompts a seemingly logical question (Figure 1): would initiating biologics earlier, for example when asthma is still mild or moderate, increase the likelihood of achieving remission? First, this question depends on the definition of remission, as clinical remission does not necessarily imply biological remission, which would require normalization of the pathobiology. Furthermore, the question assumes that severe asthma represents the end stage of progression from mild to moderate disease. As asthma severity is largely defined by treatment intensity required to achieve control, progression is inferred from therapy escalation, a metric confounded by prescribing practices, adherence, exposures and comorbidities. Current evidences and key knowledge gaps on early intervention with biologics for asthma remission. AHR, airway hyperresponsiveness; BISE, benralizumab in mild‐to‐moderate asthma trial; FeNO, fractional exhaled nitric oxide; IgE, immunoglobulin E; IL‐13, interleukin 13; IL‐33, interleukin 33; IL‐4, interleukin 4; IL‐5, interleukin 5; IL‐5Rα, interleukin 5 receptor alpha subunit; JAK, Janus kinase; T2, Type 2 (inflammation); TSLP, thymic stromal lymphopoietin. In the NORDSTAR cohort, the largest study describing longitudinal trajectories, approximately 80% of patients were classified as having ‘consistently severe,’ ‘intermittent severe’, or ‘sudden‐onset severe asthma’ [5]. Interestingly, in the ‘gradual‐onset severe asthma’ trajectory, OCS prescriptions were already evident a decade before the onset of severe asthma and, if interpreted as short burst courses, corresponded to an estimated 0.7–1.5 OCS‐treated exacerbations/year, suggesting that initial severity assessment might have been lenient. Other studies corroborate that over 90% of patients with mild or moderate asthma remain in those categories over time [6, 7]. Of note, escalation in the daily dose of inhaled corticosteroids may be driven by factors other than uncontrolled T2 inflammation, such as comorbidities that can amplify asthma severity and recurrent airway infection. A treatable‐traits‐based multidimensional intervention has been shown to improve asthma control and reduce asthma exacerbations [8], suggesting that some patients considered candidates for therapeutic escalation in fact have untreated extrapulmonary traits. Even among the few patients who truly progress to severe asthma, identifying those most likely to progress can be challenging. Several risk factors—such as exacerbation despite medium‐dose ICS, high short‐acting beta‐agonist use, recurrent respiratory infections, and biomarkers of T2 inflammation—can help identify patients at higher risk of progression to severe disease, with selected high‐risk profiles showing up to a 30% five‐year risk of progression [6]. However, this also indicates that progression is not deterministic and is likely influenced by additional biological, environmental, clinical, and healthcare‐related factors. In clinical practice, treatment escalation (and therefore severity ascertainment) is often triggered by symptom burden, whereas objective measures of lung function are underused outside specialist care and may be only intermittently incorporated even in specialized settings [9]. In addition, the role of exacerbations in mild asthma remains difficult to quantify because exacerbation ascertainment is partly shaped by clinicians' thresholds for prescribing OCS and patients' expectations of receiving them. Although T2 inflammation has been associated with remodelling and accelerated lung‐function decline [9], lung‐function trajectories and current severe asthma criteria do not map neatly onto one another. This discordance reflects that severity definitions are not exclusively a consequence of long‐term structural change. Even if we accept that suppressing T2 inflammation early could prevent remodelling and avert future severity, targeting only specific cytokines or receptors of the T2 inflammation cascade with biologics and neglecting the impact of recurrent infections and airway hyperreactivity may still be insufficient [7, 10, 11]. Differences exist between mild and severe asthma airway inflammation. Most of the patients with severe asthma (> 70%) have an eosinophilic phenotype, and nearly all severe asthma is sustained by T2 inflammation [12]. In contrast, mild asthmatics who are usually atopic tend to have early‐onset disease without evidence of persistent eosinophilic disease in over half of the patients. Most of these are children. In this context, allergic sensitization to aeroallergens may contribute to disease pathogenesis either as an independent driver of airway inflammation and remodelling or as a susceptibility factor for more severe viral infections [13]. This underscores the heterogeneity of biology in milder stages and the prominent role of other contributors, such as environmental and viral triggers and Th1/Th17 inflammation [12]. Although elevated blood eosinophils (≥ 300 cells/μL) and FeNO (≥ 50 ppb) are associated with a higher risk of exacerbations even among GINA steps 1 and 2 [14], other T2 mechanisms that may contribute to airway remodelling—and potentially to disease progression—remain incompletely understood and should not be ignored. These may include severe allergy to animal antigens, ILC2, mast cell–mediated disease, and increased airway hyperresponsiveness, which can promote extracellular matrix deposition through mechanosensing in airway fibroblasts [10, 15, 16]. However, there are signals that immune remodelling in asthma may occur. Indirect evidence comes from childhood‐onset mild allergic asthma, in which spontaneous biological remission occurs in roughly one quarter of patients [17]. From a therapeutic perspective, the clearest example of an intervention with disease‐modifying properties is allergen immunotherapy. The PAT study showed that pollen immunotherapy in children with seasonal rhinoconjunctivitis reduced asthma development, with benefits lasting even after treatment discontinuation [18]. To date, no evidence exists that biologics can modify asthma's natural history to achieve biological remission. Assuming that early immunomodulation with biologics targeting T2 inflammation could increase the likelihood of remission, it may be more plausible to aim for upstream or pleiotropic pathways (IgE, TSLP or IL‐4/IL‐13 signalling) [19] than to inhibit downstream cytokines, such as IL‐5. Currently there is little evidence to support this assumption. Raised eosinophils in mild asthma, unlike severe asthma, could be a biomarker of inflammation without necessarily representing the dominant driver of the disease [20] and, as such, targeting them with biologics may not lead to better outcomes. The benralizumab clinical trial program demonstrated this, with increasing asthma severity in the study populations being associated with better treatment outcomes [21]. In conclusion, simply moving treatment initiation with biologics ‘earlier’ into milder disease risks constructing an expensive disease‐modification narrative that is not yet supported by sufficient evidence (Figure 1). By contrast, earlier initiation of biologics appears beneficial primarily for patients with asthma that is already severe, reinforcing the importance of minimizing diagnostic delay [22]. Because progression appears to be rare (and likely multifactorial) [10] for most patients with mild asthma, positioning biologics as preventive risks overtreatment, medicalization, and substantial increase in healthcare costs. Early intervention should not automatically be equated with ‘early biologics’. We should define and test early intervention packages that address the drivers most likely to shape long‐term trajectories (immunologic, environmental, behavioural, infections, and developmental). Indeed, without addressing comorbidities and modifiable risk factors, even biologics could be only a partial solution. Finally, remission frameworks should specify which biological domains must normalize before early intervention can reasonably be considered disease modification. Remission in severe asthma is achievable and worth pursuing. Well‐designed research programs specifically targeting clinical remission and, once clearly defined, biological remission through deep phenotyping and tailored interventions—including early interventions—remain a worthy objective and should be tested in different cohorts, encompassing both early‐onset and late‐onset asthma. However, we must be cautious of the risk of drifting from evidence‐based medicine toward expectation‐based medicine. Author Contributions Jaime Bernaola: writing – original draft. Santi Nolasco: writing – original draft. Parameswaran Nair: conceptualization, supervision, writing – review and editing. Funding The authors have nothing to report. Conflicts of Interest Santi Nolasco received honoraria for lectures, presentations, and advisory boards from AstraZeneca, GlaxoSmithKline, and Sanofi. Jaime Bernaola received honoraria for lectures and presentations from AstraZeneca. Parameswaran Nair is supported by the Frederick Hargreave Teva Innovation Chair in Airway Diseases. Parameswaran Nair reports grants and personal fees from AstraZeneca, grants and personal fees from Sanofi, grants and personal fees from Roche, grants from Foresee, grants from Methapharm, and personal fees from Arrowhead pharma, outside the submitted work. Data Availability Statement Data sharing not applicable to this article as no datasets were generated or analysed during the current study. References Associated Data Data Availability Statement Data sharing not applicable to this article as no datasets were generated or analysed during the current study.